First AD

Second AD

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss 5-year data for ponatinib in pretreated CP-CML.

5-Year Data for Ponatinib in Pretreated CP-CML from the OPTIC Trial

OncLive News Network®

® video programs provide lively discussions, insights, and expert perspectives on important issues facing today’s cancer care professionals. One variation of the program, titled, 

, comprises live virtual or on-site premium reporting for oncologists as it covers the latest news and information coming out of the largest annual oncology conferences. 

Hematologic Oncology

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Unpacking Key Data in Chronic Myeloid Leukemia After ASH 2024

Moffitt Cancer Center

Cancer Centers

Partner

Mayo Clinic

5-year Data for Ponatinib in Pretreated CP-CML from the OPTIC Trial

Implications of the FDA Approval of Asciminib for Newly Diagnosed, Ph+ CP-CML

Factors That Influence Treatment Decisions in Later-Line CML

Emerging Mutation Analysis from the OPTIC Trial

Dosing Strategies for Ponatinib in CML and ALL

The Role of Frontline Ponatinib Plus Chemo in Ph+ ALL

Selecting a TKI in Subsequent Lines of Therapy in CML

Highlighting Key CML/ALL Data Presented at ASH 2024